Trial Profile
Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms CAINTA
- 14 Mar 2023 Results published in the Clinical Cancer Research
- 18 Jul 2020 Status changed from recruiting to completed.
- 30 Jul 2014 New trial record